Tego Science Inc banner
T

Tego Science Inc
KOSDAQ:191420

Watchlist Manager
Tego Science Inc
KOSDAQ:191420
Watchlist
Price: 12 980 KRW 1.56% Market Closed
Market Cap: ₩105.3B

Relative Value

The Relative Value of one Tego Science Inc stock under the Base Case scenario is hidden KRW. Compared to the current market price of 12 980 KRW, Tego Science Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Tego Science Inc Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Tego Science Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Tego Science Inc
KOSDAQ:191420
103.9B KRW 16.9 -32 -23.4 -19.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
362.5B USD 5.9 86.6 14.4 20
US
Amgen Inc
NASDAQ:AMGN
187.5B USD 5.1 24.3 14.1 14.1
US
Gilead Sciences Inc
NASDAQ:GILD
170.3B USD 5.8 20 12.5 15.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.3B USD 9.6 29.2 21.9 22.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.5B USD 5.4 17.2 12.6 14.4
AU
CSL Ltd
ASX:CSL
66.8B AUD 3.1 33.9 11.2 14.1
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.3B USD 11.1 131.9 73.8 82
P/S Multiple
Revenue Growth P/S to Growth
KR
T
Tego Science Inc
KOSDAQ:191420
Average P/S: 3 063 004.3
16.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.8
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
10%
0.5
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
11.1
34%
0.3
P/E Multiple
Earnings Growth PEG
KR
T
Tego Science Inc
KOSDAQ:191420
Average P/E: 49
Negative Multiple: -32
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
86.6
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.3
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.2
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
13%
1.3
AU
CSL Ltd
ASX:CSL
33.9
10%
3.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
131.9
84%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
T
Tego Science Inc
KOSDAQ:191420
Average EV/EBITDA: 22.9
Negative Multiple: -23.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.4
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
18%
0.7
AU
CSL Ltd
ASX:CSL
11.2
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
73.8
67%
1.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
T
Tego Science Inc
KOSDAQ:191420
Average EV/EBIT: 26.1
Negative Multiple: -19.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.5
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
23%
0.6
AU
CSL Ltd
ASX:CSL
14.1
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
82
69%
1.2
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett